Moderna shares surge after company says experimental mRNA cancer treatment passed a key test
- Moderna shares more than doubled after the company reported initial results from an experimental cancer treatment study.
- The treatment, called intismeran, is an mRNA-based cancer vaccine being developed with Merck and designed to be tailored to individual patients' tumor mutations.
- In the study, intismeran was combined with Merck's immunotherapy drug Keytruda for melanoma patients.
- The companies said the combination kept patients alive without cancer returning or spreading longer than Keytruda alone.
- They did not provide data on overall survival or the exact length of time patients remained cancer-free.
- Moderna said the results will be presented at an upcoming international medical meeting.
Moderna said initial results from a study of an experimental cancer treatment showed the therapy met a key test, sending its shares up sharply on Wednesday. The stock rose more than 120% to $140.12 a share. Merck shares also moved higher, rising about 11%.
The treatment, called intismeran, is an mRNA-based cancer vaccine that Moderna and Merck are developing together. It is designed to be customized for individual patients based on mutations found in their tumors.
In the study, the companies tested intismeran together with Merck's Keytruda in melanoma patients and compared that approach with Keytruda alone. They said the combination helped patients stay free of cancer returning or spreading for longer than the single-drug approach.
The companies did not release the exact duration of benefit or say whether the treatment improved overall survival. They said the study findings will be presented at an upcoming international medical meeting. The market impact is potentially positive for Moderna and Merck, given the stronger share prices after the announcement.
Moderna股价大涨，公司称其实验性mRNA癌症疗法通过关键测试
Moderna表示，一项实验性癌症治疗研究的初步结果显示，该疗法通过了一个关键测试，消息公布后公司股价周三大幅上涨，涨幅超过120%，收于每股140.12美元。默克股价也上涨了约11%。
这项名为intismeran的疗法是一种mRNA癌症疫苗，由Moderna与默克共同开发，旨在根据患者肿瘤中的突变情况进行个体化定制。
在这项研究中，两家公司将intismeran与默克的Keytruda联合用于黑色素瘤患者，并与单独使用Keytruda的方案进行比较。公司称，联合治疗组患者在癌症未复发或未扩散方面持续时间更长。
两家公司没有公布这一获益持续了多久，也没有说明该疗法是否改善总体生存期。公司表示，研究结果将在即将举行的一场国际医学会议上展示。就市场影响而言，这一消息对Moderna和默克的股价构成潜在利好。